Stock Taper
SCREENER COMPARE ANY 2 STOCKS
BCAB
BIOATLA, INC.
NASDAQ
$1.74
▼ DOWN 44.75% (-1.41)

KEY STATISTICS

Market Cap$2.88 M
52w High$71.50
52w Low$1.51
Dividend Yield—
Frequency—
P/E-0.12
Volume1.03M
Shares Out.1.66M

COMPANY

LEADERSHIP

Jay Short
CHIEF EXECUTIVE
Jay Short

COMPENSATION 2026

Salary$734,820
Stock Awards$144,428
Incentive Plan Pay$0
All Other Comp.$0
Total$879,248

ABOUT

SECTOR
Healthcare
WENT PUBLIC
December 16, 2020
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
41

PRICE TARGET

Target High$250.00
Target Low$250.00
Target Median$250.00
Target Consensus$250.00

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.$5.59M
NOV
12
THU

SPLIT RECORD

DATETYPERATIO
2026-04-06Reverse1:50

PRICE

$1.74 ▼ DOWN 44.75% (−$1.41)
OVERLAYS
$1.65$1.80$1.95$2.109:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM1.74

About BioAtla, Inc.

https://www.bioatla.com ↗

BioAtla, Inc. is a San Diego-based biopharmaceutical company developing targeted antibody-drug conjugates and immunotherapies for various solid tumors and cancers.

INDUSTRY

Biotechnology

A PRODUCT BIOATLA, INC. IS KNOWN FOR

Ozuriftamab vedotin (BA3021)
Ozuriftamab vedotin (BA3021)

Ozuriftamab vedotin is a BioAtla Phase 2 ADC targeting ROR2 in solid tumors, with FDA Fast Track for certain head and neck cancers, utilizing the company's CAB platform.

COMPETITORS

COMPETITOR
ADCT COMPARE
CTMX COMPARE
HOWL COMPARE
STRO COMPARE

Revenue by Products

IconPRODUCTQ2-2021
Service$300K

ETFS HOLDING THIS STOCK

ETFS HOLDING
4
LISTED HERE
3
RANKED BY POSITION SIZE
VXF
0.00% · 9.2K
XCHA.L
0.00% · 7.5K
STSB
0.12% · 187

INSTITUTIONAL OWNERSHIP

SHARES OWNED
100.00%
HOLDERS
58
TOP 12 OF 58 · RANKED BY POSITION SIZE
Acorn Capital Advisors, LLC
5.4M sh · $865.01K
Millennium Management LLC
2.8M sh · $443.82K
Vanguard Group Inc
1.9M sh · $1.34M
Tang Capital Management LLC
1.4M sh · $945.23K
Acadian Asset Management LLC
1.2M sh · $198K
Marshall Wace, Llp
891.6K sh · $508.2K
Renaissance Technologies LLC
800.6K sh · $550.75K
Blackrock Inc.
791.6K sh · $1.08M
Geode Capital Management, LLC
689.2K sh · $110.98K
Boxer Capital, LLC
686.3K sh · $1.21M
Deutsche Bank AG\
525.4K sh · $362.49K
Blackrock, Inc.
480.9K sh · $273.03K

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
SHORT JAY M PHD
Sale · 259 shares
2026-05-31
★
OFFICER: CHIEF MEDICAL OFFICER
Sievers Eric
Sale · 134 shares
2026-05-31
★
OFFICER: CHIEF MEDICAL OFFICER
Sievers Eric
Sale · 360 shares
2026-03-11
★
OFFICER: CHIEF FINANCIAL OFFICER
Vasquez Christian
Sale · 175 shares
2026-03-11

SECTORS PEERS

PEERPRICE
PYPD$5.07COMPARE
ANVS$1.72COMPARE
CELU$1.58COMPARE
VERU$2.63COMPARE
EVAX$3.01COMPARE
RVPH$0.52COMPARE
BTAI$0.18COMPARE